Filtered By:
Management: Funding
Countries: Finland Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 5 results found since Jan 2013.
Arterys partners with Combinostics on neuro AI software
Finnish imaging software developer Arterys will offer neuroradiology artificia...Read more on AuntMinnie.comRelated Reading:
Arterys brings Avicenna AI stroke software on board
Arterys receives $28M in funding
MaxQ AI, Arterys partner on AI-based image analysis
Funding for imaging AI companies tops $1.2B
How AI will become an integral part of standard care
Source: AuntMinnie.com Headlines - November 28, 2021 Category: Radiology Source Type: news
Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1
1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy
2Humanitas Clinical and Research Center-IRCCS, Milan, Italy
3Humanitas University, Milan, Italy
4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research
Work stress and risk of death in men and women with and without cardiometabolic disease: a multicohort study
Publication date: Available online 5 June 2018 Source:The Lancet Diabetes & Endocrinology Author(s): Mika Kivimäki, Jaana Pentti, Jane E Ferrie, G David Batty, Solja T Nyberg, Markus Jokela, Marianna Virtanen, Lars Alfredsson, Nico Dragano, Eleonor I Fransson, Marcel Goldberg, Anders Knutsson, Markku Koskenvuo, Aki Koskinen, Anne Kouvonen, Ritva Luukkonen, Tuula Oksanen, Reiner Rugulies, Johannes Siegrist, Archana Singh-Manoux, Sakari Suominen, Töres Theorell, Ari Väänänen, Jussi Vahtera, Peter J M Westerholm, Hugo Westerlund, Marie Zins, Timo Strandberg, Andrew Steptoe, John Deanfield Background Although som...
Source: The Lancet Diabetes and Endocrinology - June 6, 2018 Category: Endocrinology Source Type: research
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Publication date: Available online 29 January 2018 Source:The Lancet Haematology Author(s): Mats Jerkeman, Christian Winther Eskelund, Martin Hutchings, Riikka Räty, Karin Fahl Wader, Anna Laurell, Helle Toldbod, Lone Bredo Pedersen, Carsten Utoft Niemann, Christina Dahl, Hanne Kuitunen, Christian H Geisler, Kirsten Grønbæk, Arne Kolstad Background Regimens based on ibrutinib alone and lenalidomide and rituximab in combination show high activity in patients with relapsed or refractory mantle cell lymphoma. We hypothesised that the combination of all three drugs would improve efficacy compared with previously published ...
Source: The Lancet Haematology - January 30, 2018 Category: Hematology Source Type: research
Finland extends due date on Nexstim R & D loans
Nexstim said today that the Finnish Funding Agency for Innovation has agreed to extend the due date for repayment of 2 of its research & development project loans.
According to the agreement, the company was supposed to provide cash repayments up to €1.8 million ($2 million) between 2017 and 2019. Now, that range has been pushed back to between 2020 and 2022. The company has to fully repay both loans to Tekes by the end of 2023, Nexstim said.
“This agreement, which reschedules our R&D loan repayment payments to Tekes, will have a positive effect on Nexstim’s cash flow and will help to support our workin...
Source: Mass Device - June 2, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Funding Roundup Neurological Wall Street Beat Nexstim Source Type: news